Navigation Links
InterMune to Present at BMO Healthcare Conference
Date:7/30/2008

BRISBANE, Calif., July 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference in New York on August 6, 2008 at 10:00 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
2. InterMune to Present at Jefferies Healthcare Conference
3. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
4. InterMune to Present at Citigroup Healthcare Conference
5. InterMune to Present at Bank of America Health Care Conference
6. InterMune to Present at Deutsche Bank Health Care Conference
7. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
8. Evotec Expands Collaboration With InterMune
9. InterMune to Present at the SIGnificant Options in Healthcare Conference
10. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
11. InterMune Announces Closing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, ... sell research and genetic testing lab equipment from two different leading institutes. This highly ... Northeast regions of the United States. This 1-day online auction will take place ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017 Shareholder ... an investigation into whether the board members of CoLucid ... fiduciary duties in connection with the proposed sale of ... a biopharmaceutical company that develops small molecules for the ... 2017, CoLucid announced it had signed a definitive merger ...
(Date:1/18/2017)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF) ... and commercializes proprietary technologies and products for advanced ... that Cameron Prange , President of Kingsdale ... Board of Directors.  Mr. Prange,s resignation is related ... limited both his ability to act on behalf ...
(Date:1/17/2017)... ... January 17, 2017 , ... MS Technologies™ and Bayer ... GT Soybean Performance System will combine industry-leading genetics with a double herbicide-tolerant trait ... new Balance® Bean herbicide. The Balance™ GT Soybean Performance System will benefit soybean ...
Breaking Biology Technology:
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):